Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

Sample Collection Clinical Trial

Official title:

VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00067054
• Other study ID #: 030263
• Secondary ID: 03-I-0263
• Status: Recruiting
• Start date: September 10, 2003

Study information

• Verified date: May 29, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: OPS Team, VRC
• Phone: Not Listed
• Email: vaccines[@]nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study collects specimens from volunteers for use in studies by NIAID's Vaccine Research Center. A number of different types of specimens or samples can be collected, including blood, urine, body fluids or secretions, skin swabs, or skin biopsies. The samples are used for medical research, including the study of HIV, hepatitis, and other diseases; immune system responses, such as responses to vaccinations or infections; and for research on vaccine development. Blood samples may be collected either by ordinary blood drawing (phlebotomy) or by apheresis, a procedure for collecting a larger quantity of blood cells or plasma than would be possible through simple blood drawing. For this procedure, the subject lies on a recliner or couch. Blood is removed through a needle in the vein of one arm and spun in a machine that separates out the desired component (plasma or white blood cells). The remainder of the blood is returned either through the same needle or through a needle in the other arm. The procedure takes about 1 to 3 hours. Volunteers who are 18 years of age and older, including participants in other NIH research protocols, may be eligible. Individuals who have a condition that the research staff considers a reason not to make a sample donation will be excluded from the study. Participants may have only one sample collected or may be asked to undergo repetitive sample collection procedures, depending upon the requirements of the particular research project for which the samples are being collected. Each individual's enrollment is for a 1-year period, which can be extended.

Description:

Study Description: This protocol is designed to collect human specimens, such as blood, mucosal secretions, skin swabs, skin biopsy, or body fluids to support medical research. These samples will be used by researchers in their work on the development of vaccines and monoclonal antibodies, to study the correlates of immunity related to infectious diseases and allergies, and in laboratory work related to the development and/or validation of immunological and other relevant assays. Standard phlebotomy and apheresis procedures will be utilized to safely obtain necessary quantities of blood and cells. Objectives: To obtain human biological specimens such as blood (via phlebotomy), plasma or peripheral blood mononuclear cells (PBMC) samples (via apheresis), mucosal secretions, skin swabs, body fluids, and skin biopsy to support medical research. Study Population: Adults ages 18 years and older. Protocol Plan: Subjects, including healthy volunteers and patients with an infection or with an allergic or autoimmune condition who consent to participate in this study, will undergo standard medical procedures to obtain biological specimens. Samples may be collected at clinic visits by study staff or at home by the participant and shipped to the NIH by the participant. Study Duration: Individual subjects may donate samples as often as permitted by their institution s guidelines. The IRB-approved protocol will remain open and undergo annual continuing review by the IRB. Endpoints: There are no specific endpoints in this study, as samples are collected for investigations conducted in research laboratories to address questions related to vaccine and monoclonal antibody development, as noted in the study description. Therefore, there is no analysis plan for this protocol. This protocol will be conducted in accordance with Good Clinical Practices for human research solely for the purpose of obtaining samples for research laboratories. Samples will be identified only by a subject identification number. Non-personally identifying information that will be linked to a subject ID only, such as demographic information, aspects of the medical history, laboratory parameters, recent immunizations or medications, genetic tests and other medical information, may be provided to researchers if needed to support the objectives of the laboratory research.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

• INCLUSION CRITERIA:

A subject must meet all of the inclusion criteria, as follows:

1. Age 18 years or older

2. Able and willing to complete the informed consent process

3. Willing to provide blood or other samples that will be stored indefinitely and used for future research

4. Able to provide proof of identity to the acceptance of the clinician completing the enrollment process; when informed consent is obtained by telephone or a telehealth visit, the investigator obtaining consent will also confirm proof of identity. EXCLUSION CRITERIA: A subject will be excluded from protocol participation if there is presence of a condition that the attending physician considers to be a contraindication to the specimen collection procedures. SKIN BIOPSY ELIGIBILITY CRITERIA:

The skin biopsy eligibility includes the following:

1. No known allergies to the local anesthetic to be used

2. No history of keloid formation

3. No known coagulation disorders

4. Not pregnant or breast feeding APHERESIS ELIGIBILITY CRITERIA: To undergo an apheresis procedure, a subject must have no medical contraindications. All apheresis procedures performed under this protocol are solely for research purposes. Subjects participating in an active clinical research protocol may participate in the apheresis protocol if the total amount of blood drawn does not exceed NIH guidelines or a site's institutional guidelines. A study clinician will complete a checklist for apheresis eligibility before referring a subject for apheresis. At the NIH, prior to the scheduled procedure, the subject must have a venous assessment performed by apheresis staff to determine suitability for apheresis. For Healthy Volunteers:

A healthy volunteer must meet all the following criteria prior to the procedure:

1. Afebrile (temperature <= 37.50 degrees C)

2. Weight >=110 pounds

3. Adequate bilateral antecubital venous access

4. Hemoglobin >= 12.5 g/dL for women; >= 13.0 g/dL for men within 56 days prior to apheresis procedure.

5. Platelets > 150,000 K/uL within 56 days prior toapheresis procedure.

6. No cardiovascular instability as indicated by a) history of medically significant cardiac arrhythmia within the last 12 months, or b) ischemic cardiovascular disease within the last 12 months, or c) heart rate outside of the 50 - 100 beats/minute interval (on 3 successive readings), or d) blood pressure greater than 180 mmHg (systolic) or 100 mmHg (diastolic) on 3 successive readings

7. No current lung or kidney disease

8. No known coagulation disorder

9. No sickle cell disease

10. No active or chronic hepatitis

11. No intravenous injection drug use in the past 5 years

12. Not breast feeding

13. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) performed by a VRC study clinician within 72 hours prior to the apheresis procedure Infectious Disease Patients:

A patient with an infectious disease must meet all of the following criteria:

1. Weight >= 110 pounds

2. Afebrile (temperature <= 37.5 degrees C)

3. Adequate bilateral antecubital venous access

4. No cardiovascular instability as indicated by a) history of medically significant cardiac arrhythmia within the last 12 months, or b) ischemic cardiovascular disease within the last 12 months, or c) heart rate outside of the 50 - 100 beats/minute (on 3 successive readings), or d) blood pressure greater than 180/100 mmHg (on 3 successive readings)

5. No current lung or kidney disease

6. No known coagulation disorder

7. No receipt of clotting factor concentrates in the past 5 years

8. Hemoglobin >= 9.0 g/dL within 56 days prior to apheresis procedure

9. Platelets >= 50,000 K/uL within 56 days prior to apheresis procedure

10. White Blood Cell WBC >= 2.0 K/uL within 56 days prior to apheresis procedure

11. Not breast feeding

12. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) performed by a VRC study clinician within 72 hours prior to the apheresis procedure

Related Conditions & MeSH terms

• Sample Collection

Locations

Country	Name	City	State
Puerto Rico	University of Puerto Rico Medical Sciences Campus	San Juan
United States	National Institutes of Health Clinical Center	Bethesda	Maryland
United States	EvergreenHealth Medical Center	Kirkland	Washington

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  Puerto Rico, 

References & Publications (3)

Braine HG, Elfenbein GJ, Mellits ED. Peripheral blood lymphocyte numbers, lymphocyte proliferative responses in vitro, and serum immunoglobulins in regular hemapheresis donors. J Clin Apher. 1985;2(3):213-8. doi: 10.1002/jca.2920020302. — View Citation

Heal JM, Horan PK, Schmitt TC, Bailey G, Nusbacher J. Long-term follow-up of donors cytapheresed more than 50 times. Vox Sang. 1983;45(1):14-24. doi: 10.1111/j.1423-0410.1983.tb04118.x. — View Citation

Strauss RG, Maguire LC, Koepke JA, Thompson JS. Effect of intermittent-flow centrifugation leukapheresis on donor leukocyte counts. Acta Haematol. 1980;63(3):128-31. doi: 10.1159/000207383. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sample collection only	This protocol does not have an analysis primary outcome measure, but rather will be conducted in accordance with Good Clinical Practices for human research solely for the purpose of obtaining samples for research laboratories. Samples will be identified only by protocol identification number. Subject data, such as demographic information, aspects of medical history, laboratory parameters, recent immunizations or medications, HLA type, genetic tests and other medical information may be provided (identified by study number, but not subject name) to researchers if needed to support the objectives of the laboratory research.	end of study

External Links

•   NIH Clinical Center Detailed Web Page